Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers

被引：3
|
作者：
Kato, Renpei [1 ]
Obara, Wataru [1 ]
机构：
[1] Iwate Med Univ, Dept Urol, Morioka, Iwate, Japan
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2022年 / 22卷 / 07期
关键词：
anti-PD-1/PD-L1; therapy; biomarker; renal cell carcinoma; PD-L1; expression; peripheral blood biomarkers; CIRCULATING TUMOR DNA; CHECKPOINT; EXPRESSION;
D O I：
10.1080/14737140.2022.2087631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：667 / 669
页数：3
相关论文
共 50 条
  • [21] PD1/PD-L1 therapy in metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Lemberger, Ursula
    Hassler, Melanie R.
    Fajkovic, Harun
    Schmidinger, Manuela
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 534 - 541
  • [22] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [23] Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy
    Cao, Yiyi
    Li, Wenbo
    Wang, ZhengJie
    Pang, Hua
    TUMORI JOURNAL, 2021, 107 (04): : 282 - 291
  • [24] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [25] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
    Zhu, Jason
    Armstrong, Andrew J.
    Friedlander, Terence W.
    Kim, Won
    Pal, Sumanta K.
    George, Daniel J.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [26] Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Ikeda, Sadakatsu
    Goodman, Aaron M.
    Cohen, Philip R.
    Jensen, Taylor J.
    Ellison, Christopher K.
    Frampton, Garrett
    Miller, Vincent
    Patel, Sandip P.
    Kurzrock, Razelle
    NPJ GENOMIC MEDICINE, 2016, 1
  • [27] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [28] Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
    Zhang, Chaoxu
    Fan, Yibo
    Che, Xiaofang
    Zhang, Min
    Li, Zhi
    Li, Ce
    Wang, Shuo
    Wen, Ti
    Hou, Kezuo
    Shao, Xinye
    Liu, Yunpeng
    Qu, Xiujuan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [29] Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
    de Jong, Florus C.
    Rutten, Vera C.
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [30] Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
    Chen, Miaomiao
    Wang, Siliang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
12345